Oragenics, Inc. (NYSE American: OGEN) has entered into a significant partnership with Lantern Bioworks, marked by the formalization of a materials transfer agreement. This collaboration follows rigorous testing and validation of biological samples from Oragenics.

Orsini Specialty Pharmacy has been chosen by Amicus Therapeutics as the provider for Pombiliti™ (cipaglucosidase alfa-atga) and Opfolda™ (miglustat), a combination treatment approved for specific patients with late-onset Pompe disease.

Mabwell, an innovative biopharmaceutical company with an entire industry chain, has announced that the first patient has been dosed in a phase Ib/II trial of its novel Nectin-4 targeting ADC (R&D code: 9MW2821) in combination with a PD-1 inhibitor for the treatment of locally advanced or metastatic urothelial carcinoma.

Everest Medicines has received approval from the Taiwan Food and Drug Administration (TFDA) for its New Drug Application (NDA) for XERAVA® (eravacycline).

Calliditas Therapeutics AB has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its drug setanaxib for the treatment of Alport syndrome.

Nexus Pharmaceuticals, LLC has announced its receipt of approval from the U.S. Food and Drug Administration (FDA) for Fluorescein Injection, USP. Usman Ahmed, President and Chief Executive Officer of Nexus Pharmaceuticals, expressed enthusiasm about this FDA approval, stating

Chrysalis BioTherapeutics, Inc. has received permission from the U.S. Food and Drug Administration (FDA) to commence human clinical trials focused on treating acute lung failure. With the approval of its Investigational New Drug (IND) Application

AcuraStem, a biotechnology company focused on developing treatments for neurodegenerative diseases, has entered into a licensing agreement with Takeda to collaborate on the development and commercialization of AcuraStem's PIKFYVE targeted therapeutics, including AS-202, an antisense oligonucleotide (ASO) designed for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Chime Biologics, a prominent Contract Development and Manufacturing Organization (CDMO) specializing in biologics, has entered into a strategic cooperation agreement with Kings Pharm. Under this agreement, Chime Biologics will utilize its extensive expertise in biosimilar projects to provide Kings Pharm

The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR)